Swedish Orphan Biovitrum

Swedish Orphan Biovitrum, known as Sobi, is a global biopharmaceutical company that develops and delivers medicines for people living with rare and debilitating diseases. Its areas of expertise are haematology, immunology and specialty care, and its portfolio includes recombinant clotting factor therapies and extended half-life therapies for haemophilia and other bleeding disorders. The company operates in 30 countries and is headquartered in Sweden.

The present company was formed in 2010 through the merger of Swedish Orphan International and Biovitrum, though its corporate lineage extends considerably further back. The business traces its origins to the 1930s, when it began as a Swedish brewery subsidiary researching residual biological materials, and it pioneered blood plasma fractionation in the 1940s.

Sobi's technical work spans protein therapeutics, blood plasma fractionation, recombinant clotting factor development, extended half-life therapies, vitamin research, the drying of sensitive biological materials and orphan drug development. The company describes a patient-centric focus on conditions with limited treatment options, together with a research heritage of curiosity-driven science.

Its industry footprint covers biopharmaceuticals, rare disease, haematology, immunology, specialty care, haemophilia care and orphan drugs.